KIR2DL3 抗体 (FITC)
-
- 抗原 See all KIR2DL3 抗体
- KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This KIR2DL3 antibody is conjugated to FITC
-
应用范围
- Flow Cytometry (FACS)
- 纯化方法
- The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
- 克隆位点
- DX27
- 亚型
- IgG2a kappa
- Top Product
- Discover our top product KIR2DL3 Primary Antibody
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 缓冲液
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 注意事项
- Protect from prolonged exposure to light. Do not freeze.
- 储存条件
- 4 °C
- 储存方法
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- 抗原
- KIR2DL3 (Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 (KIR2DL3))
- 别名
- CD158b (KIR2DL3 产品)
- 别名
- CD158B2 antibody, CD158b antibody, GL183 antibody, KIR-023GB antibody, KIR-K7b antibody, KIR-K7c antibody, KIRCL23 antibody, NKAT antibody, NKAT2 antibody, NKAT2A antibody, NKAT2B antibody, p58 antibody, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antibody, KIR2DL3 antibody
- 背景
- CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.
- 途径
- Cancer Immune Checkpoints
-